Among R/R de novo DLBCL patients, ROR1 positivity appeared to be associated with shorter overall survival, which in multivariable analysis was independent of some prognostic factors but not the frequently used clinical markers such as cell of origin and IPI. The gene discussed is ROR1; the disease is diffuse large B-cell lymphoma.